SAG and metabolic syndrome: Based on similar observations focused on arrestin signaling, HCAR2 was in 2009 highlighted by Lefkowitz and coworkers as a prime example of how the development of a biased agonist which signals through G protein but devoid of arrestin signaling, would provide the beneficial effect on dyslipidemia without the flushing side effects32.